Skip to main content

Table 1 The clinical manifestations of disease in each study group

From: The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Clinical symptoms and signs

Study group

Number (%)

Control group

Number (%)

Blurred vision

3 (15)

8 (26.6)

Diplopia

4 (20)

4 (13.3)

Blindness

1 (5)

0 (0)

Gait problem

5 (25)

2 (6.6)

Paresthesia

3 (15)

2 (6.6)

Muscle weakness

0 (0)

3 (10)

Dysarthria

0 (0)

1 (3.3)

Bladder dysfunction

0 (0)

1 (3.3)